Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,019.00DKK
10:59am EST
Change (% chg)

kr.-31.00 (-2.95%)
Prev Close
kr.1,050.00
Open
kr.1,030.00
Day's High
kr.1,040.00
Day's Low
kr.1,017.00
Volume
260,843
Avg. Vol
325,881
52-wk High
kr.1,489.00
52-wk Low
kr.994.80

Latest Key Developments (Source: Significant Developments)

Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​
Monday, 22 Jan 2018 02:06am EST 

Jan 22 (Reuters) - GENMAB ::ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS.‍RECEIVES USD 50 MILLION FROM NOVARTIS AS PAYMENT FOR LOST POTENTIAL MILESTONES AND ROYALTIES​.‍AMOUNT WILL BE INCLUDED IN GENMAB'S 2018 GUIDANCE​.‍ROYALTIES WILL CONTINUE TO BE EARNED ON NET SALES OF ARZERRA​.  Full Article

Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights
Tuesday, 9 Jan 2018 02:58pm EST 

Jan 9 (Reuters) - Genmab A/S ::GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO.MAJOR SHAREHOLDER ANNOUNCEMENT.  Full Article

Biotech Genmab sees 2018 expense growth of 40-50 pct
Tuesday, 12 Dec 2017 01:27am EST 

Dec 12 (Reuters) - FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA: :DENMARK'S GENMAB SEES 2018 EXPENSE GROWTH OF 40-50 PERCENT DRIVEN BY PIPELINE INVESTMENTS.SAYS ROYALTY FUNDS 100 PCT OF EXPENSE INVESTMENT.GENMAB TO CONDUCT NEW AND LARGER TISOTUMAB VEDOTIN TRIALS IN 2018.SAYS 6 PRE-CLINICAL PRODUCTS RAPIDLY ADVANCING.SAYS 2018 WILL BE 6TH YEAR OF PROFITABILITY.  Full Article

Genmab Achieves $20 Million Milestone In Daratumumab Collaboration With Janssen
Wednesday, 29 Nov 2017 03:42pm EST 

Nov 29 (Reuters) - Genmab A/S ::GENMAB ACHIEVES USD 20 MILLION MILESTONE IN DARATUMUMAB COLLABORATION WITH JANSSEN AND UPDATES FINANCIAL GUIDANCE.GENMAB - EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2,240 - 2,440 MILLION.GENMAB - PAYMENT RELATES TO PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB & DEXAMETHASONE IN AMYLOIDOSIS.  Full Article

Genmab: $50 mln milestone payment in collaboration on Darzalex
Thursday, 16 Nov 2017 09:31pm EST 

Nov 17(Reuters) - GENMAB A/S : :SAID ON FRIDAY WILL RECEIVE MILESTONE PAYMENT OF USD 50 MILLION IN DARZALEX COLLABORATION WITH JANSSEN BIOTECH, INC..SAID MILESTONE TRIGGERED BY SALES OF DARZALEX REACHING USD 1 BILLION IN A CALENDAR YEAR.THE MILESTONE WAS INCLUDED IN GENMAB’S 2017 FINANCIAL GUIDANCE PUBLISHED ON NOVEMBER 14, 2017.  Full Article

‍Genmab says expect 2017 revenue to be in range of DKK 2,110 – 2,310 mln
Tuesday, 14 Nov 2017 02:50pm EST 

Nov 14 (Reuters) - Genmab ::‍GENMAB ACHIEVES USD 25 MILLION MILESTONE FOR FIRST COMMERCIAL SALE OF DARZALEX® (DARATUMUMAB) IN JAPAN AND UPDATES FINANCIAL GUIDANCE​.GENMAB SAYS ‍EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2.110 - 2.310 MILLION​.GENMAB-EXPECT DARZALEX ROYALTIES TO REMAIN IN RANGE OF DKK 930 - 1,100 MILLION WHICH ARE BASED ON ESTIMATED USD 1,100 - 1,300 MILLION OF DARZALEX SALES IN 2017​.‍NOW EXPECT OPERATING INCOME FOR 2017 TO BE APPROXIMATELY DKK 1,060 - 1,260 MILLION, COMPARED TO DKK 900 - 1,100 MILLION IN PREVIOUS GUIDANCE​.  Full Article

Genmab Q3 net loss DKK 5.7 mln, misses estimates
Wednesday, 8 Nov 2017 11:01am EST 

Nov 8 (Reuters) - GENMAB A/S ::GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2017 <<>>.‍REVENUE WAS DKK 1,348 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 889 MILLION IN FIRST NINE MONTHS OF 2016​.‍OPERATING INCOME WAS DKK 641 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 345 MILLION IN FIRST NINE MONTHS OF 2016​.‍IS MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017 AND REITERATED ON SEPTEMBER 27, 2017​.Q3 REVENUE DKK ‍​ 323.4 MILLION (REUTERS POLL DKK 333 MILLION).Q3 OPERATING RESULT DKK ‍​ 58.3 MILLION (REUTERS POLL DKK 59 MILLION).Q3 NET LOSS DKK ‍​5.7 MILLION (REUTERS POLL PROFIT DKK 67.3 MILLION).  Full Article

Genmab: ‍worldwide net sales of darzalex $317 mln in Q3
Tuesday, 17 Oct 2017 06:52am EDT 

Oct 17 (Reuters) - GENMAB A/S :GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2017.‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 317 MILLION IN Q3 OF 2017​.‍GENMAB WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.​.  Full Article

Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
Tuesday, 10 Oct 2017 06:20am EDT 

Oct 10 (Reuters) - Genmab A/S :Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer.Genmab - ‍companies plan to start enrolling patients by first half of 2018​.Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​.  Full Article

Genmab: Darzalex approved for relapsed or refractory multiple myeloma in Japan
Wednesday, 27 Sep 2017 01:49am EDT 

Sept 27 (Reuters) - GENMAB A/S :ANNOUNCES APPROVAL OF DARZALEX® (DARATUMUMAB) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN JAPAN .‍TO RECEIVE USD 25 MILLION IN MILESTONE PAYMENTS UPON FIRST COMMERCIAL SALE IN JAPAN​.‍IF FIRST COMMERCIAL SALE IS ACHIEVED PRIOR TO YEAR END, GENMAB EXPECTS TO UPDATE ITS FINANCIAL GUIDANCE AT THAT TIME​.FIRST COMMERCIAL SALE COULD TAKE PLACE IN EITHER LATE 2017 OR EARLY 2018, GENMAB IS NOT UPDATING ITS FINANCIAL GUIDANCE FOR 2017​.  Full Article

BRIEF-Genmab ‍2017 Operating Profit Beats Expectations

* ‍PROJECTED REVENUE FOR 2018 CONSISTS PRIMARILY OF DARZALEX ROYALTIES OF APPROXIMATELY DKK 1,750 MLN THAT ARE BASED ON AN ESTIMATED USD 2.0 - 2.3 BLN OF DARZALEX NET SALES IN 2018​